DOCS: AI Investment Year And Healthcare Moat Set To Support Reengagement

The updated Doximity analyst price target edges up slightly to $25.42, as analysts balance concerns about slower digital advertising growth, tougher competition, and heavier AI investment against a still supportive longer term rationale. This is reflected in a modestly higher fair value and P/E assumption.

Analyst Commentary

Recent research on Doximity has turned more cautious, with many firms cutting price targets and repositioning ratings as they reassess growth, execution, and the impact of heavier AI spending on valuation. Even so, there are still some analysts who see reasons to stay constructive on the stock over a longer time frame.

Bullish Takeaways

Some bullish analysts continue to see Doximity as a potential AI winner. They argue that the current investment cycle and margin pressure could eventually support a broader product set and justify higher earnings power than implied by current P/E multiples.
Despite lower price targets, several firms that keep Buy or Outperform ratings point to perceived value in the shares relative to their updated fair value work, especially after the stock reaction to the weaker fiscal 2027 outlook.
A few research notes highlight Doximity's new AI Search offering for pharma as a possible future growth driver. They suggest that successful commercialization could support a re-acceleration in revenue growth and a re-rating of the stock.
Some analysts see the recent revenue and EBITDA beats as evidence that, even with softer guidance, Doximity can still execute against near-term expectations. This supports maintaining constructive views on longer-term execution.

Bearish Takeaways

Bearish analysts repeatedly point to slowing digital advertising growth and intensifying competition as key risks. They argue that this could cap Doximity's growth profile and keep the stock range bound despite lower valuations.
Several firms express concern that Doximity has shifted from a clear growth leader to a more mature, challenged platform, with rising risk of incremental share erosion and limited visibility into revenue growth beyond the near term.
There is broad caution around the fiscal 2027 outlook and AI investment year, with multiple research notes flagging heavier AI and compute costs pressuring margins before any clear revenue payoff. They see this as increasing execution risk.
Analysts from JPMorgan and Goldman, along with others, emphasize that slower growth, regulatory and macro uncertainty around pharma marketing budgets, and leadership changes could leave valuation compressed until Doximity can show more consistent execution and clearer returns on its AI spend.

What’s in the News for Doximity

Doximity is in focus after recent stock analysis highlighted its digital platform for U.S. medical professionals, including a HIPAA compliant AI assistant and clinical documentation tools, and discussed analyst views on potential upside based on an average price target and the company’s operating profile. Source: Doximity, Inc. (DOCS) Stock Analysis: Exploring A 26.85% Potential Upside In Health Information Services.
The Schall Law Firm and other parties have launched investor investigations and potential class actions following Doximity’s May 13, 2026 Q4 and full year results. These results missed consensus revenue estimates and were followed by a 23% share price decline and commentary about near term margin pressure from higher AI investment. Source: Doximity Faces Investor Fraud Investigation After Q4 Earnings Miss and Share Drop.
Doximity issued fiscal first quarter 2027 and full year 2027 guidance, indicating expected revenue of US$151 million to US$152 million for the quarter ending June 30, 2026 and US$664 million to US$676 million for the year ending March 31, 2027.
The company announced a new integration with Aledade, bringing Doximity’s Clinical AI Suite, including its Scribe ambient notetaking tool and Ask clinical AI assistant, into Aledade Assist so primary care physicians can access documentation and evidence based clinical support inside their existing workflow.
Doximity disclosed chief financial officer changes, with former CFO Anna Bryson resigning while on medical leave, interim responsibilities taken on by Chief Accounting Officer Siddharth Sitaram, and the appointment of Matthew Sonefeldt as CFO and principal financial officer effective June 8, 2026. He brings experience from DocuSign, Atlassian, LinkedIn, and other companies.

Valuation Changes for Doximity

Fair Value: Updated slightly to $25.42 from $25.15, reflecting a small upward adjustment in the valuation model.
Discount Rate: Adjusted marginally to 8.03% from 8.02%, indicating a very small change in the assumed risk profile.
Revenue Growth: Held effectively steady at 6.05%, suggesting no material change in the modeled top line growth trajectory for Doximity.
Net Profit Margin: Kept essentially unchanged at 27.59%, indicating a consistent view on long term profitability.
Future P/E: Ticked up modestly to 25.68x from 25.40x, signaling a slightly higher earnings multiple in the updated assumptions.

2 views

Key Takeaways

AI-powered workflow tools and high platform engagement drive deeper customer retention, higher revenue per user, and expanding long-term margins.
Broad client demand and digital marketing trends position Doximity for sustained growth, improved sales efficiency, and earnings stability through diversified revenue streams.
Heavy short-term investment in free AI features, dependence on pharma marketing, regulatory risks, and slowing user growth could constrain revenue, margin, and earnings expansion.

Catalysts

About Doximity

Operates as a digital platform for medical professionals in the United States.What are the underlying business or industry changes driving this perspective?

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time-supporting long-term revenue and margin expansion.
Strong, broad-based demand from pharmaceutical, SMB, and health system clients-fueled by a digital-first shift in pharma marketing strategies and expansion of self-service/commercial portals-positions Doximity for sustained top-line growth, particularly as digital advertising continues supplanting traditional outreach, bolstering both revenue growth and sales efficiency.
The stickiness and daily-use nature of Doximity's telehealth, scheduling, and workflow tools-amplified by ongoing healthcare workforce shortages-reinforce Doximity's value proposition and increase switching costs, supporting resilient net revenue retention (>118%) and reducing future churn, which underpins stable earnings and improving EBITDA margins.
Growing penetration and upsell to enterprise health systems (including 17 of the top 20 U.S. systems) and accelerated momentum in recruitment/curative products leverages the regulatory and industry push toward digital, efficient, value-based care solutions, expanding addressable market and diversifying revenue streams, contributing to greater earnings visibility and lower cyclicality.
Internal and product-facing AI initiatives are driving meaningful productivity gains and operational leverage (headcount flat while revenue grows, AI-enabled client portal efficiency), which is likely to support further EBITDA margin expansion and robust free cash flow, even as the company invests heavily in new growth vectors.

Doximity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Doximity's revenue will grow by 6.0% annually over the next 3 years.
Analysts assume that profit margins will shrink from 30.4% today to 27.6% in 3 years time.
Analysts expect earnings to reach $212.2 million (and earnings per share of $1.27) by about June 2029, up from $196.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $250.8 million in earnings, and the most bearish expecting $167.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.7x on those 2029 earnings, up from 18.7x today. This future PE is lower than the current PE for the US Healthcare Services industry at 26.4x.
Analysts expect the number of shares outstanding to decline by 2.36% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.03%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

While Doximity is successfully launching AI products like Scribe and integrating new acquisitions, management's decision to offer key advanced features (e.g., Scribe, Pathway corpus, DocsGPT) for free in the near-term could limit direct revenue growth and slow the monetization of its third act; this may delay the positive financial impact typically expected from new product launches, constraining revenue and earnings expansion in the medium term.
Doximity's continued heavy reliance on pharmaceutical marketing spend as its primary revenue driver exposes it to risks from regulatory or policy changes such as potential direct-to-consumer (DTC) bans, industry consolidation, or reduced pharma budgets, which could materially impact top-line growth and profitability over the long run.
The company is experiencing strong broad-based client and user engagement growth, but mentions of "policy uncertainty" and the need for "measured guidance" in the second half of the year highlight ongoing vulnerability to regulatory and healthcare budget fluctuations, introducing uncertainty into renewal rates, revenue predictability, and net margins.
While user engagement metrics are hitting record highs, a significant portion of physician adoption may plateau in the coming years as the platform nears saturation among U.S. clinicians; this dynamic can limit future network effect-driven growth, constricting both revenue momentum and margin leverage opportunities over the longer term.
Although management expects AI investments to drive long-term efficiency, current and upcoming stock-based compensation ("high teens" as a percentage of revenue through 2027) and ongoing OpEx increases for AI personnel and infrastructure may pressure net margins, dilute EPS, and offset some near-term gains from operational scale, particularly if new monetization from AI features lags expectations.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $25.42 for Doximity based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $42.0, and the most bearish reporting a price target of just $18.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $769.1 million, earnings will come to $212.2 million, and it would be trading on a PE ratio of 25.7x, assuming you use a discount rate of 8.0%.
Given the current share price of $20.07, the analyst price target of $25.42 is 21.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Doximity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks